



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

(hospitalised between Jan 1, 2020, and Feb 4, 2020). All patients had been diagnosed with cirrhosis by abdominal CT scan, CT during arterial portography, or liver biopsy.

Between Jan 1, and Feb 3, 2020, messages relating to precautions to take against COVID-19, including protective measures aimed at preventing patient infections and precautions for cirrhotic complications (panel), were sent to outpatients via WeChat every 3 days for a total of 12 times. Feedback from the patient was collected every day via WeChat. For inpatients, new precautionary procedures were implemented, including hospital staff training, health education for patients and their companions, new processes for diagnosis and treatment, emergency plans, and suggestions for discharging patients (panel). After 14 days, on Feb 18, 2020, a questionnaire was sent to all participants to investigate their symptoms and satisfaction with the messaging system.

Of the 111 patients, the mean age was 58.7 years (SD 10.7) (appendix 2, pp 1–2), most of whom came from Wuhan, the city hardest hit by the outbreak (appendix 2, p 3). One patient died after 19 days in hospital because of multiple organ failure.

At follow-up, none of our participants had clinical symptoms suggestive of SARS-CoV-2 infection. By contrast, five (2%) of 250 patients without cirrhosis and six (16%) of 38 health-care workers were diagnosed with COVID-19 by casual testing in our ward. Several outpatients complained about mild gastrointestinal and respiratory symptoms, which were resolved by rest, proton pump inhibitors, and probiotics (appendix 2, p 2).

As an additional comparator, we calculated the incidence of COVID-19 among 101 inpatients with decompensated cirrhosis at five other hospitals in Wuhan over the same period, where our approach had not been implemented. 17 (17%) of these

101 patients were diagnosed with COVID-19 ($p=0.018$ vs our group; appendix 2, p 4). This simple approach could be an effective means of preventing COVID-19 in patients with decompensated cirrhosis. However, our sample size is small and larger studies are needed.

We declare no competing interests. We thank Xia Tian (Department of Gastroenterology, TongRen Hospital of Wuhan University, Wuhan Third Hospital, Wuhan, China), Hui Long (Department of Gastroenterology, Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China); Xiaowei Wu and Ji Wang (Department of Gastroenterology, Hanyang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China); Huimin Liu (Department of Gastroenterology, The Second Affiliated Hospital of Jiangnan University, Wuhan Fifth Hospital, Wuhan, China); and Ying Xu (Department of Gastroenterology, Wuhan Hankou Hospital, Wuhan, China) for providing data regarding their inpatients with cirrhosis. YX and HP contributed equally.

Yong Xiao, Hong Pan, Qian She, Fen Wang, *Mingkai Chen
kaimingchen@163.com

Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China (YX, QS, MC); Department of Plastic Surgery, TongRen Hospital of Wuhan University, Wuhan Third Hospital, Wuhan, China (HP); and Department of Gastroenterology, Third XiangYa Hospital Central South University, Changsha, China (FW)

- Zhang C, Shi L, Wang F. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; published online March 4. DOI:10.1016/S2468-1253(20)30057-1.
- Strnad P, Tacke F, Koch A, Trautwein C. Liver—guardian, modifier and target of sepsis. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 55–66.

COVID-19 and the liver: little cause for concern

The largest study on COVID-19 to date¹ showed that the prevalence of elevated aminotransferases and bilirubin in people faring worst was at least double that of others. Although clinically significant liver dysfunction was not quantified, this and other studies have led some to suggest that this finding might present clinical challenges.² Close inspection of the available data supports a higher prevalence of abnormal aminotransferase levels in

severe COVID-19 disease, but these studies actually suggest that clinically significant liver injury is uncommon, even when data for the most severely ill patients are selected (table).

Although high levels of positive end expiratory pressure can contribute to hepatic congestion by increasing right atrial pressure and impeding venous return, data suggest that many patients admitted to hospital with COVID-19 have liver blood test abnormalities without mechanical ventilation. Furthermore, the distribution of aminotransferase levels among patients with COVID-19 do not support hypoxic hepatitis being a common phenomenon, according to the published literature. Drug-induced liver injury is a possible contributing factor to the observed abnormal liver blood test abnormalities after therapeutics begin and should be considered by clinicians, but mild liver test derangement is present at baseline in many patients with COVID-19 before significant medication use. Several studies have reported elevated levels of creatinine kinase and lactate dehydrogenase or myoglobin in association with COVID-19 severity (table). It is therefore possible that aminotransferase elevations do not necessarily arise from the liver alone and that COVID-19 infection might induce a myositis similar to that observed in severe influenza infections.

It has been proposed that COVID-19 causes direct liver injury via a viral hepatitis, but we believe that there are alternative explanations. First, the derangement of liver function is clearly mild. Second, when liver function tests for patients with different durations of symptoms are examined, there is no evidence that later presentation is associated with greater liver function derangement.³ The only post-mortem liver biopsy from a patient with COVID-19 showed only microvesicular steatosis, a common finding in sepsis.⁴ Most

See Online for appendix 2



Published Online
March 20, 2020
[https://doi.org/10.1016/S2468-1253\(20\)30084-4](https://doi.org/10.1016/S2468-1253(20)30084-4)

	Group	Patients	Alanine aminotransferase (IU)	Aspartate aminotransferase (IU)	Prothrombin time (s)	Bilirubin (µmol/L)	Elevated lactate dehydrogenase, creatinine kinase, or myoglobin	Mortality (%)
Guan et al (2020)	ICU or death	67	Not known	Not known	Not known	Not known	Yes	22% (day 51)
Huang et al (2020)	ICU	13	49 (29–115)	44 (32–70)	12.2 (11.2–13.4)	14.0 (11.9–32.9)	Yes	38% (day 37)
Chen et al (2020)	Hospitalised	99	39 (22–53)	34 (26–48)	11.3 (1.9)	15.1 (7.3)	Yes	11% (day 24)
Wang et al (2020)	ICU	36	35 (19–57)	52 (30–70)	13.2 (12.3–14.5)	11.5 (9.6–18.6)	Yes	17% (day 34)
Shi et al (2020)	Hospitalised	81	46 (30)	41 (18)	10.7 (0.9)	11.9 (3.6)	Unclear	5% (day 50)
Xu et al (2020)	Hospitalised	62	22 (14–34)	26 (20–32)	Not known	Not known	Unclear	0% (day 34)
Yang et al (2020)	ICU	52	Not known	Not known	12.9 (2.9)*	19.5 (11.6)*	Not described	62% (day 28)
Extracted from all studies above	Chronic liver disease	42	Not known	Not known	Not known	Not known	Not known	0–2%†

Data is mean (SD) or median (IQR) depending on the original study. *Non-survivor intensive care unit (ICU) group. †One patient was either admitted to an intensive care unit or died. Details of references can be found in the appendix.

Table: Liver test abnormalities from various COVID-19 studies, identifying the most severe disease categories where possible

See Online for appendix

importantly, other respiratory viruses produce similar elevations of liver function biomarkers, which is thought to relate to hepatic damage from immune interactions involving intrahepatic cytotoxic T cells and Kupffer cells.⁵ This phenomenon waxes and wanes in parallel with respiratory viral disease and in the absence of hepatic viral replication, which might explain why worse outcomes were not seen in the 42 patients with chronic liver disease and COVID-19 who had outcome data (table).

Hepatic dysfunction in severe COVID-19 is accompanied by greater activation of coagulative and fibrinolytic pathways, relatively depressed platelet counts, climbing neutrophil counts and neutrophil to lymphocyte ratios, and high ferritin levels.⁶ Although these markers are seen as non-specific markers of inflammation, we believe that they fit the paradigm of disease severity coinciding with a failure of innate immune regulation.⁷ Such unbalanced immunity favours NETosis and coagulation activation and possibly also alters systemic iron metabolism secondary to macrophage activation.⁸ Notably, this alteration of immune balance occurs with increased age, and older patients might therefore be expected to fare

worse, with a greater reliance on this pathway.⁹

Clinicians cannot be complacent about the risks of COVID-19 in patients with chronic liver diseases and cirrhosis, because these patients have poor immune function and worse outcomes from acute respiratory distress syndrome than the rest of the critically ill population.¹⁰ However, we believe that collateral liver damage from virally induced cytotoxic T cells and the induction of a dysregulated innate immune response is a more probable explanation for the association between deranged liver markers and COVID-19 disease severity. Furthermore, we suspect that what is termed COVID-19-induced hepatic damage is predominantly a clinical distraction. We urge clinicians and the scientific community to focus attention towards viral control and modulating innate immune dysfunction in COVID-19.

We declare no competing interests.

**Mansoor N Bangash, Jaimin Patel, Dhruv Parekh*

mansoor.bangash@uhb.nhs.uk

Liver Intensive Care Unit, University Hospitals National Health Service Foundation Trust, Birmingham B15 2GW, UK (MNB, JP, DP); and Birmingham Liver Failure Research Group, Institute of Clinical Sciences (MNB) and Birmingham Acute Care Research Group, Institute of Inflammation and Ageing (JP, DP), College of Medical and Dental

Sciences, University of Birmingham, Birmingham, UK

- Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *N Engl J Med* 2020; published online Feb 28. DOI:10.1056/NEJMoa2002032.
- Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; published online March 4. [http://dx.doi.org/10.1016/S2468-1253\(20\)30057-1](http://dx.doi.org/10.1016/S2468-1253(20)30057-1).
- Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; published online Feb 24. [http://dx.doi.org/10.1016/S1473-3099\(20\)30086-4](http://dx.doi.org/10.1016/S1473-3099(20)30086-4).
- Koskinas J, Gomatos IP, Tiniakos DG, et al. Liver histology in ICU patients dying from sepsis: a clinico-pathological study. *World J Gastroenterol* 2008; **14**: 1389–93.
- Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. *Am J Pathol* 2006; **168**: 1057–59.
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; published online Feb 7. DOI:10.1001/jama.2020.1585.
- Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. *Am J Pathol* 2011; **179**: 199–210.
- Sapey E, Patel JM, Greenwood H, et al. Simvastatin improves neutrophil function and clinical outcomes in pneumonia. A pilot randomized controlled clinical trial. *Am J Resp Crit Care Med* 2019; **200**: 1282–93.
- Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* 2015; **282**: 20143085.
- Gacouin A, Locufier M, Uhel F, et al. Liver cirrhosis is independently associated with 90-day mortality in ARDS patients. *Shock* 2016; **45**: 16–21.